Quality of Life in Children Cured of Retinoblastoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00278031|
Recruitment Status : Recruiting
First Posted : January 18, 2006
Last Update Posted : October 4, 2016
|Condition or disease|
Retinoblastoma is the most common eye tumor of children. It can present in one eye (unilateral) or in both eyes (bilateral). The bilateral form is always hereditary.
Retinoblastoma is a highly curable tumor. Using a combination of surgery, chemotherapy, radiation and local treatment modalities to the eye, over 98% of patients are cured. This means that most children diagnosed with retinoblastoma will become long-term survivors.
The use of surgery (taking out one eye), chemotherapy, and radiation may be associated with long term side-effects, some of which may have significant impact on the quality of life of the child. In addition, in case where the disease is hereditary, additional psychological issues arise.
The aim of our study is to assess, in a comprehensive and standardized fashion, the long term quality of life in children who were treated for retinoblastoma, and who are currently alive and well.
The assessment will include the use of questionnaires that assess quality of life, as well as participation in age-appropriate activities.
Each child, and his/her parent, will be interviewed and the questionnaires completed. The process will take about one hour for each child. No risk or discomfort to the child is involved.
|Study Type :||Observational|
|Estimated Enrollment :||35 participants|
|Official Title:||Quality of Life in Children Cured of Retinoblastoma|
|Study Start Date :||March 2006|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
- Change in quality of life [ Time Frame: Baseline and 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00278031
|Contact: Michael Weintraub, MDemail@example.com|
|Hadassah Medical Organization, Jerusalem, Israel||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Arik Tzukert, DMD 00 972 2 6776095 firstname.lastname@example.org|
|Contact: Hadas Lemberg, PhD 00 972 2 6777572 email@example.com|
|Principal Investigator: Michael Weintraub, MD|
|Principal Investigator:||Michael Weintraub, MD||Hadassah Medical Organization|